This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Vivus, Arena Rise on New Insurance Coverage For Obesity Pills

BOSTON ( TheStreet) -- Shares of Vivus (VVUS - Get Report) and Arena Pharmaceuticals (ARNA - Get Report) rose Wednesday after Aetna (AET - Get Report) said it would provide medical benefit coverage for the companies' respective prescription weight-loss pills.

The nation's third-largest insurer issued a policy bulletin update on Tuesday in which Vivus' Qsymia and Arena's Belviq were added to a list of "medically necessary weight loss reduction medicines."

Aetna's coverage decision could provide a financial incentive for obese patients to consider weight-loss pills. For this reason, Vivus shares rose 13% to $11.70; Arena shares increased 3% to $9.16 in Wednesday trading

Approximately 30% of patients prescribed Qsymia choose not to pick up their prescription due to the high out-of-pocket cost. This high rate of prescription abandonment has been cited by Vivus executives as one of the significant reasons for the weight-loss pill's disappointing commercial launch.

Vivus said approximately 20% of patients were receiving insurance reimbursement coverage for Qsymia with an average co-pay of $60 per month. Aetna's decision to cover Qsymia and Arena's Belviq is a significant addition.

Aetna's coverage of Qsymia and Belviq is as a medical benefit and not a pharmacy benefit, and comes with other restrictions. The medicines will be considered medically necessary only for members who fail to lose at least one pound per week after at least six months on a weight-loss regimen that includes diet and exercise. Members also have to have a body mass index greater than 30 or a body mass index greater than 27 plus other risk factors.

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
SYM TRADE IT LAST %CHG
AET $114.90 0.18%
ARNA $4.25 1.20%
VVUS $2.56 -0.97%
AAPL $132.62 0.94%
FB $81.02 0.67%

Markets

DOW 18,260.04 -25.70 -0.14%
S&P 500 2,130.51 -0.31 -0.01%
NASDAQ 5,101.7740 +10.98 0.22%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs